A multicenter phase 2 randomized trial of single-agent ALIMTA [pemetrexed] or ALIMTA with sequentially administered GEMZAR [gemcitabine] as first-line chemotherapy in elderly patients or patients who are not eligible for platinum-based chemotherapy with advanced NSCLC [non-small cell lung cancer]

Trial Profile

A multicenter phase 2 randomized trial of single-agent ALIMTA [pemetrexed] or ALIMTA with sequentially administered GEMZAR [gemcitabine] as first-line chemotherapy in elderly patients or patients who are not eligible for platinum-based chemotherapy with advanced NSCLC [non-small cell lung cancer]

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2007

At a glance

  • Drugs Gemcitabine; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 25 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top